N18.4

Chronic kidney disease, stage 4

## Overview of Chronic Kidney Disease Stage 4 (N18.4)Chronic Kidney Disease (CKD) Stage 4, coded as N18.4 in ICD-10, represents a severe reduction in kidney function, characterized by a glomerular filtration rate (eGFR) between 15 and 29 mL/min/1.73 m². At this stage, the kidneys are significantly damaged and are struggling to adequately filter waste products, regulate fluid and electrolyte balance, and produce essential hormones. This profound impairment often leads to overt symptoms of uremia and an increased risk of serious complications, necessitating careful medical management and preparation for kidney replacement therapy.### PathophysiologyThe pathophysiology of CKD Stage 4 involves progressive and irreversible loss of functional nephrons, which are the basic filtering units of the kidney. Regardless of the underlying cause, the sustained loss of nephrons leads to adaptive hyperfiltration and hypertrophy in the remaining healthy nephrons. While initially compensatory, this adaptation eventually causes further injury and scarring (glomerulosclerosis and tubulointerstitial fibrosis), perpetuating a vicious cycle of decline. As the eGFR falls below 30 mL/min/1.73 m², the kidneys lose their ability to maintain homeostasis. This results in the accumulation of nitrogenous waste products (e.g., urea, creatinine, various uremic toxins), fluid overload, electrolyte imbalances (hyperkalemia, hyperphosphatemia), metabolic acidosis, and impaired production of hormones such as erythropoietin (leading to anemia) and active vitamin D (contributing to mineral and bone disorders). The systemic effects of these derangements manifest as the uremic syndrome, impacting nearly every organ system. Furthermore, CKD Stage 4 significantly increases cardiovascular risk due to hypertension, dyslipidemia, chronic inflammation, and vascular calcification.### Clinical PresentationPatients in CKD Stage 4 often present with a variety of symptoms related to the accumulation of uremic toxins and the systemic complications of kidney dysfunction. While early stages of CKD can be largely asymptomatic, Stage 4 typically sees more noticeable manifestations. Common symptoms include persistent fatigue, weakness, generalized malaise, and difficulty concentrating due to uremic encephalopathy. Nausea, vomiting, anorexia, and an unpleasant metallic taste (dysgeusia) are frequent gastrointestinal complaints. Fluid retention can lead to peripheral edema, dyspnea (due to pulmonary edema), and exacerbation of hypertension. Skin changes such as pruritus (itching) and pallor (due to anemia) are common. Musculoskeletal issues include muscle cramps, restless legs syndrome, and bone pain secondary to renal osteodystrophy. Neurological symptoms may also include paresthesias, reduced nerve conduction velocity, and, in severe cases, asterixis or seizures. Cardiovascular symptoms such as chest pain (pericarditis), palpitations, and worsening heart failure are critical concerns.### Diagnostic CriteriaThe diagnosis of CKD Stage 4 is primarily based on two key criteria present for at least three months:1. **Estimated Glomerular Filtration Rate (eGFR):** An eGFR sustained between 15 and 29 mL/min/1.73 m². This is typically calculated using serum creatinine levels and demographic factors (age, sex, race) via equations like CKD-EPI or MDRD.2. **Evidence of Kidney Damage:** This includes, but is not limited to: * **Albuminuria:** Urinary albumin excretion rate >30 mg/24 hours or albumin-to-creatinine ratio (ACR) >30 mg/g. * **Hematuria:** Persistent microscopic or macroscopic hematuria, after excluding urological causes. * **Structural Abnormalities:** Detected by imaging studies (e.g., polycystic kidneys, hydronephrosis, renal scarring). * **Pathological Abnormalities:** Identified through kidney biopsy. * **History of Kidney Transplantation.**Regular monitoring of eGFR and proteinuria is crucial for staging and tracking disease progression.### Standard of CareManagement of CKD Stage 4 is multidisciplinary, focusing on slowing disease progression, managing complications, and preparing the patient for kidney replacement therapy (KRT), which includes dialysis or kidney transplantation.* **Blood Pressure Control:** Aggressive blood pressure control (target <130/80 mmHg) is critical using ACE inhibitors or Angiotensin Receptor Blockers (ARBs) as first-line agents, especially in patients with proteinuria, as these also help reduce proteinuria and preserve kidney function.* **Glycemic Control:** For diabetic patients, strict glycemic control (HbA1c target usually <7%) is essential to prevent further kidney damage.* **Dietary Modifications:** A low-sodium diet helps manage fluid overload and hypertension. Protein restriction (0.6-0.8 g/kg/day) may reduce uremic symptoms and slow GFR decline. Restriction of potassium and phosphorus is often necessary to prevent hyperkalemia and hyperphosphatemia.* **Anemia Management:** Anemia of CKD is common. It is managed with iron supplementation (oral or intravenous) and erythropoiesis-stimulating agents (ESAs) if hemoglobin levels fall below target ranges (e.g., <10 g/dL), under careful monitoring to avoid cardiovascular risks.* **Mineral and Bone Disorder (CKD-MBD):** Management involves phosphate binders (e.g., calcium acetate, sevelamer) to control hyperphosphatemia, and active vitamin D analogs (e.g., calcitriol, paricalcitol) to suppress secondary hyperparathyroidism.* **Metabolic Acidosis:** Oral bicarbonate supplementation may be initiated to correct metabolic acidosis, which can worsen bone disease and muscle wasting.* **Cardiovascular Risk Reduction:** Aggressive management of dyslipidemia with statins, smoking cessation, and lifestyle modifications are paramount given the high cardiovascular risk in CKD.* **Vaccinations:** Patients should receive vaccinations against influenza, pneumococcal disease, and hepatitis B due to increased susceptibility to infections.* **Referral to Nephrology:** All patients with CKD Stage 4 should be managed by a nephrologist to optimize care and facilitate timely planning for KRT.* **Preparation for KRT:** Discussions regarding dialysis modalities (hemodialysis, peritoneal dialysis) and kidney transplantation should begin early, along with creation of vascular access (e.g., arteriovenous fistula) if hemodialysis is anticipated.This comprehensive approach aims to improve patient quality of life and outcomes in the face of advanced kidney disease.

Clinical Symptoms

  • Fatigue and weakness
  • Generalized malaise
  • Nausea and vomiting
  • Anorexia and weight loss
  • Metallic taste in mouth (dysgeusia)
  • Peripheral edema (swelling of legs, ankles, hands)
  • Shortness of breath (dyspnea), especially on exertion or due to fluid overload/pulmonary edema
  • Hypertension (often difficult to control)
  • Pruritus (itching)
  • Pallor (pale skin)
  • Muscle cramps
  • Restless legs syndrome
  • Bone pain
  • Difficulty concentrating, memory problems (uremic encephalopathy)
  • Paresthesias (numbness or tingling)
  • Insomnia or sleep disturbances
  • Easy bruising or bleeding tendencies (due to platelet dysfunction)
  • Decreased urine output (oliguria), though some patients may maintain urine output
  • Sexual dysfunction (erectile dysfunction, decreased libido)
  • Amenorrhea in women
  • Bad breath (uremic fetor)
  • Cold intolerance
  • Reduced appetite

Common Causes

  • Diabetes mellitus (diabetic nephropathy)
  • Hypertension (hypertensive nephrosclerosis)
  • Glomerular diseases (e.g., glomerulonephritis, focal segmental glomerulosclerosis, IgA nephropathy)
  • Polycystic kidney disease (PKD) and other inherited kidney diseases
  • Autoimmune diseases (e.g., systemic lupus erythematosus, vasculitis)
  • Obstructive nephropathy (e.g., benign prostatic hyperplasia, kidney stones, strictures, tumors)
  • Tubulointerstitial diseases (e.g., chronic pyelonephritis, analgesic nephropathy, reflux nephropathy)
  • Advanced age
  • Obesity
  • Smoking
  • High-sodium diet
  • High-protein diet
  • Family history of kidney disease
  • Cardiovascular disease
  • African American, Hispanic, or Asian descent (higher prevalence in some populations)
  • Recurrent acute kidney injury episodes
  • Certain medications (e.g., long-term NSAID use, nephrotoxic drugs)

Documentation & Coding Tips

Always document the confirmed GFR (Glomerular Filtration Rate) and albuminuria status to support CKD staging and progression. Clearly state the chronicity and how the stage was determined (e.g., sustained GFR below threshold for >3 months).

Example: Patient seen today with known Chronic Kidney Disease. Recent labs (03/15/2024) show eGFR 28 mL/min/1.73m^2 (MDRD formula, stable for 6 months), and UACR 350 mg/g. This confirms CKD Stage 4 with severe albuminuria. Etiology remains uncontrolled Type 2 Diabetes Mellitus with long-standing hypertension. Patient reports increased fatigue and occasional lower extremity edema. Plan: Continue Lisinopril 20mg daily, adjust dose based on potassium. Referral to Nephrology for co-management, dietary counseling for low-sodium/low-protein diet initiated. Education provided on monitoring symptoms and avoiding NSAIDs. Condition is chronic and managed acutely for symptom control.

Billing Focus: Documentation of specific eGFR and UACR values, chronicity (>3 months), confirmed stage, and explicit link to etiology (Type 2 Diabetes, HTN) provides robust support for N18.4 and associated comorbidity codes. Mention of 'stable for 6 months' reinforces chronicity.

Specify the underlying etiology of CKD whenever possible. Common causes include diabetes, hypertension, glomerulonephritis, polycystic kidney disease, and autoimmune diseases. Documenting the cause allows for more precise coding (e.g., E11.22 for diabetic CKD) and a clearer clinical picture.

Example: Patient presents for follow-up of ESRD management. Confirmed CKD Stage 4 (eGFR 25 mL/min/1.73m^2) due to long-standing, poorly controlled Type 2 Diabetes Mellitus (HbA1c 9.2%) and essential hypertension. Patient is symptomatic with worsening generalized weakness and persistent pruritus. Medications reviewed: Insulin Glargine, Metformin (reduced dose per nephrology), Lisinopril. Patient is counseled on adherence to diabetic diet and blood pressure control. This chronic condition is actively managed with ongoing monitoring of renal function and diabetes control.

Billing Focus: Identifying the etiology (Type 2 Diabetes Mellitus, Essential Hypertension) allows for coding of related conditions (E11.22 for T2DM with CKD, I12.9 for Hypertensive CKD). This paints a complete clinical picture and supports medical necessity for services related to all interacting conditions.

Document associated complications of CKD Stage 4, such as anemia, metabolic bone disease (renal osteodystrophy), hyperkalemia, fluid overload, cardiovascular disease, and malnutrition. These complications often require specific interventions and contribute to the patient's overall severity.

Example: 45-year-old male with known CKD Stage 4 (N18.4) secondary to IgA nephropathy. Today's visit notes significant anemia (Hgb 9.5 g/dL), mild peripheral edema (fluid overload, E87.70), and phosphate level 5.2 mg/dL indicating hyperphosphatemia. Discussed initiation of darbepoetin alfa for anemia and phosphate binders. Patient denies chest pain but reports increased dyspnea on exertion. Chronic condition with new acute complications requiring intervention. Active management for CKD, anemia, and electrolyte imbalance.

Billing Focus: Coding for complications like 'Anemia in chronic kidney disease' (D63.1), 'Fluid overload' (E87.70), and 'Hyperphosphatemia' (E87.3) justifies additional diagnostic tests and treatment modalities, ensuring appropriate reimbursement for the increased complexity of care.

Clearly describe the management plan, including medication adjustments, dietary recommendations, lifestyle modifications, referrals to specialists (e.g., nephrology, dietetics), and plans for renal replacement therapy education.

Example: Patient with established CKD Stage 4 (eGFR 29 mL/min/1.73m^2), etiology hypertensive nephrosclerosis. Discussed recent decline in GFR from 32 to 29. Maintained on low-sodium, low-protein diet. Increased Furosemide to 40mg BID for peripheral edema. Scheduled for renal dietitian consultation to optimize nutrition. Reviewed options for future renal replacement therapy (hemodialysis vs. peritoneal dialysis vs. transplant) and provided educational materials. Nephrology continues to co-manage. This is a chronic, progressive condition requiring multidisciplinary management.

Billing Focus: Detailed documentation of management (medication changes, dietary counseling, specialist referrals, RRT education) supports the complexity of an E/M visit. Clearly indicating 'nephrology continues to co-manage' justifies higher E/M levels if applicable and coordination of care.

When a patient with CKD is admitted for an acute event, always specify if the CKD is a contributing factor, a comorbidity, or exacerbated by the acute condition. Distinguish between acute kidney injury (AKI) and chronic kidney disease.

Example: Patient admitted with acute exacerbation of heart failure (I50.23). Baseline eGFR 27 mL/min/1.73m^2 (CKD Stage 4, N18.4, secondary to Type 2 Diabetes E11.22). Initial creatinine 2.1 mg/dL, rose to 2.8 mg/dL on admission. This represents an Acute Kidney Injury (N17.9) superimposed on Chronic Kidney Disease Stage 4. Fluid management for CHF must be balanced carefully to avoid further renal insult. Patient is hemodynamically stable. Consulting nephrology for AKI management in the setting of advanced CKD. Condition is chronic with acute, severe superimposed injury.

Billing Focus: Differentiating AKI (N17.9) superimposed on CKD Stage 4 (N18.4) and linking both to the underlying etiology (E11.22 for T2DM) ensures accurate coding of all diagnoses, reflecting the complexity of the patient's condition for appropriate inpatient billing.

Relevant CPT Codes

Related Diagnoses

Hierarchy